Two distinct mutations in gyrA lead to ciprofloxacin and nalidixic acid resistance in Campylobacter coli and Campylobacter jejuni isolated from chickens and beef cattle

J Appl Microbiol. 2006 Apr;100(4):682-8. doi: 10.1111/j.1365-2672.2005.02796.x.

Abstract

Aims: The aim of this study was to identify point mutations in the gyrA quinolone resistance determining region (QRDR) of Campylobacter coli (n = 27) and Campylobacter jejuni (n = 26) that confer nalidixic acid (NAL) resistance without conferring resistance to ciprofloxacin (CIP).

Methods and results: Point mutations in the QRDR of gyrA from C. coli and C. jejuni isolates were identified by direct sequencing. All isolates (n = 14) with minimum inhibitory concentrations (MICs) >or=4 microg ml(-1) for CIP and >or=32 microg ml(-1) for NAL possessed a missense mutation leading to substitution of Ile for Thr at codon 86. Three isolates with a missense mutation leading to a Thr86Ala substitution had MICs <4 mug ml(-1) for CIP and >or=32 microg ml(-1) for NAL.

Conclusions: These data confirm previous findings that Thr86Ile mutations confer resistance to both CIP and NAL. However, resistance to NAL alone was conferred by a single Thr86Ala mutation.

Significance and impact of the study: Resistance to NAL alone arises independently from CIP resistance. In addition, the role of other previously described point mutations in quinolone resistance is discussed.

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Anti-Infective Agents / pharmacology*
  • Bacterial Proteins / genetics
  • Campylobacter / drug effects
  • Campylobacter / genetics*
  • Campylobacter / isolation & purification
  • Campylobacter coli / drug effects
  • Campylobacter coli / genetics
  • Campylobacter coli / isolation & purification
  • Campylobacter jejuni / drug effects
  • Campylobacter jejuni / genetics
  • Campylobacter jejuni / isolation & purification
  • Cattle / microbiology*
  • Chickens / microbiology*
  • Ciprofloxacin / pharmacology*
  • DNA Gyrase / genetics*
  • Drug Resistance, Bacterial
  • Mutation, Missense / genetics
  • Nalidixic Acid / pharmacology*
  • Point Mutation / genetics

Substances

  • Anti-Infective Agents
  • Bacterial Proteins
  • Nalidixic Acid
  • Ciprofloxacin
  • DNA Gyrase